Quick Takeaways:
- BiomEdit received USDA CVB conditional licensure for CPerf LLV, an engineered Limosilactobacillus vector designed to reduce Clostridium perfringens-associated necrotic enteritis (NE) mortality in broiler chickens, based on a reasonable expectation of efficacy.
- In the pivotal study, CPerf LLV reduced NE-associated mortality by 48.7%, from 13.1% in challenged controls to 6.6% in treated birds. The non-antibiotic biologic targets C. perfringens alpha toxin and NetB toxin and is expected to be branded Optavant™ upon full licensure.
- BiomEdit has begun commercial evaluations with three major U.S. poultry producers, potentially reaching 35M+ broilers. The company will continue generating data toward full licensure while expanding its Programmable Veterinary Biologics platform and broader pipeline.
Why It Matters?
BiomEdit’s USDA conditional licensure for CPerf LLV (to be branded Optavant) creates the first genetically engineered probiotic biologic for poultry, offering a non‑antibiotic tool against necrotic enteritis-a disease costing the global broiler industry up to ~US$6B/year-and positioning BiomEdit to capture share in a large, antibiotic‑reduction‑driven market.
Source: PRnewswire
